Babar Mustafeez Mujtaba, Zaidi Najam-us-Sahar Sadaf, Tahir Muhammad
Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, H-12, Kashmir Highway, Islamabad 44000, Pakistan.
Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, H-12, Kashmir Highway, Islamabad 44000, Pakistan.
Antiviral Res. 2014 Dec;112:120-31. doi: 10.1016/j.antiviral.2014.10.013. Epub 2014 Oct 31.
Influenza virus is one of the major causes of mortality and morbidity associated with respiratory diseases. The high rate of mutation in the viral proteome provides it with the ability to survive in a variety of host species. This property helps it in maintaining and developing its pathogenicity, transmission and drug resistance. Alternate drug targets, particularly the internal proteins, can potentially be exploited for addressing the resistance issues. In the current analysis, the degree of conservation of influenza virus polymerases has been studied as one of the essential elements for establishing its candidature as a potential target of antiviral therapy. We analyzed more than 130,000 nucleotide and amino acid sequences by classifying them on the basis of continental presence of host organisms. Computational analyses including genetic polymorphism study, mutation pattern determination, molecular evolution and geophylogenetic analysis were performed to establish the high degree of conservation among the sequences. These studies lead to establishing the polymerases, in particular PB1, as highly conserved proteins. Moreover, we mapped the conservation percentage on the tertiary structures of proteins to identify the conserved, druggable sites. The research study, hence, revealed that the influenza virus polymerases are highly conserved (95-99%) proteins with a very slow mutation rate. Potential drug binding sites on various polymerases have also been reported. A scheme for drug target candidate development that can be employed to rapidly mutating proteins has been presented. Moreover, the research output can help in designing new therapeutic molecules against the identified targets.
流感病毒是导致呼吸系统疾病死亡和发病的主要原因之一。病毒蛋白质组的高突变率使其能够在多种宿主物种中存活。这一特性有助于其维持和发展致病性、传播能力及耐药性。可利用替代药物靶点,尤其是内部蛋白,来解决耐药问题。在当前分析中,流感病毒聚合酶的保守程度已作为确定其作为抗病毒治疗潜在靶点候选资格的关键要素之一进行了研究。我们根据宿主生物的大陆分布对13万多条核苷酸和氨基酸序列进行分类分析。进行了包括基因多态性研究、突变模式确定、分子进化和地球系统发育分析在内的计算分析,以确定序列间的高度保守性。这些研究确定了聚合酶,特别是PB1,为高度保守的蛋白质。此外,我们将保守百分比映射到蛋白质的三级结构上,以识别保守的、可成药的位点。因此,该研究表明流感病毒聚合酶是高度保守(95%-99%)且突变率极低的蛋白质。还报道了各种聚合酶上的潜在药物结合位点。提出了一种可用于快速突变蛋白质的药物靶点候选物开发方案。此外,研究成果有助于设计针对已确定靶点的新型治疗分子。